TITLE:
Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

CONDITION:
Intracerebral Hemorrhage

INTERVENTION:
NXY-059

SUMMARY:

      This study will determine if NXY-059 is safe in patients with an acute stroke caused by
      bleeding in the central nervous system. The primary objective was to assess the safety and
      tolerability of NXY-059 compared to placebo.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Males and females

          -  Intracerebral Hemorrhage as the cause of stroke symptoms

          -  Onset of symptoms within 6 hours

          -  Full functional independence prior to the present stroke

        Exclusion Criteria:

          -  Unconsciousness

          -  Subjects who are unlikely to complete the infusion of investigational product and/or
             are unlikely to undergo active medical management during that period due to a severe
             clinical condition.

          -  Severe illness with life expectancy less than 6 months.

          -  Known severe kidney disorder.

          -  Current known alcohol or illicit drug abuse or dependence.

          -  Pregnant or breast-feeding.

          -  Treatment with acetazolamide and methotrexate is not permitted during the infusion

          -  Participation in a previous clinical study within 7 days.

          -  Meets all other exclusion criteria
      
